Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Pathology

Internal Medicine

Surgery

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/s1470-2045(22)00487-9

License

CC-BY-NC-ND

Other Formats

PDF